Major Investor & Director Files Intent to Sell $300M in Oruka Therapeutics Stock
ORKA has more than doubled off its 52-week low of $10.966.
Summary
A major institutional investor and director has filed to sell $300 million of Oruka Therapeutics stock, representing a significant reduction in their holdings.
Key Events · Ownership and Investor Activity · ORKA
-
Intent to Sell Significant Stake
Fairmount Funds Management LLC, a 10% owner with a director on Oruka's board, has filed a Form 144 to sell 3,553,410 shares of common stock.
-
Substantial Transaction Value
The proposed sale is valued at approximately $300 million, representing 5.33% of the company's market capitalization and 5.89% of outstanding shares.
-
Conversion for Sale
The shares were acquired through the conversion of Series B Non-Voting Convertible Preferred Stock into common stock on the same day as the proposed sale, indicating a planned liquidation of a preferred position.
-
Follows Recent Positive Events
This large selling intent comes after Oruka Therapeutics reported strong Phase 2a clinical trial results and completed a $700 million public offering in April/May, suggesting profit realization.
Analysis · ORKA · Life Sciences
Fairmount Funds Management, a 10% owner and associated with a director on Oruka's board, has filed a Form 144 indicating its intent to sell over $300 million worth of common stock. This substantial proposed sale, representing over 5% of the company's market capitalization, suggests significant profit-taking by a major institutional investor following recent positive clinical trial data and a large public offering. The filing coincides with concurrent reports of actual sales of a similar magnitude by Fairmount Funds, confirming the execution of this large disposition.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORKA was trading at $86.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $10.97 to $97.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.